KR20150019548A - Composition for skin cell regeneration, anti-wrinkle and antioxidant - Google Patents
Composition for skin cell regeneration, anti-wrinkle and antioxidant Download PDFInfo
- Publication number
- KR20150019548A KR20150019548A KR20130096598A KR20130096598A KR20150019548A KR 20150019548 A KR20150019548 A KR 20150019548A KR 20130096598 A KR20130096598 A KR 20130096598A KR 20130096598 A KR20130096598 A KR 20130096598A KR 20150019548 A KR20150019548 A KR 20150019548A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- skin
- weight
- compound
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The present invention relates to a composition for skin regeneration, wrinkle reduction and antioxidation.
Collagen is a major substrate protein produced in fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, division of cells and differentiation Growth or wound healing) are known. Such collagen is reduced by aging and photo aging caused by ultraviolet irradiation, which is known to be closely related to the wrinkling of the skin. Also, in recent years, extensive research on skin aging has developed, and important functions of collagen in skin have been revealed.
Effective ingredients promoting collagen synthesis and exhibiting wrinkle-reducing effects are known. For example, retinoic acid, transforming growth factor (TGF) [non-patent document 1], animal placenta-derived protein [Patent document 1], betulinic acid [Patent document 2], chlorella extract [ Patent Documents 3 and 4] are known as collagen synthesis promoting substances. However, the above-mentioned effective ingredients are limited in the use amount due to safety problems such as irritation and redness when applied to the skin, or have insufficient effect, so that the effect of improving the skin function by promoting the collagen synthesis of the skin can not be expected.
On the other hand, active oxygen introduced from the outside of the living body or generated in the living body causes many problems such as promoting aging of the living body, cancer, and the like. Therefore, the development and research of antioxidants that inhibit oxidation by active oxygen have been performed. Antioxidants are widely distributed in copper and plants. Many phenolic compounds, flavonoids, tocopherols, vitamin C and selenium are known in fruits and vegetables. However, the antioxidant substances present in nature can not be expected to have practically sufficient effects in skin application. Therefore, although synthetic antioxidants having excellent antioxidant ability and low cost are widely used, their use is restricted due to safety concerns such as human side effects.
Accordingly, the present inventors have found that scutellarin promotes collagen synthesis of fibroblasts of the skin and inhibits collagenase activity, thereby promoting regeneration of the skin, improving wrinkles, eliminating free radicals and exhibiting antioxidative effects And completed the present invention.
Accordingly, an object of the present invention is to provide a composition for skin regeneration, wrinkle reduction and antioxidation comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
As means for solving the above problems,
There is provided a pharmaceutical composition for skin regeneration, wrinkle reduction and antioxidation comprising a compound represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]
As another means for solving the above problems,
A skin external preparation for skin regeneration, wrinkle reduction and antioxidation comprising a compound represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]
As another means for solving the above problems,
There is provided a cosmetic composition for skin regeneration, wrinkle reduction and antioxidation comprising a compound represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]
As another means for solving the above problems,
The present invention provides a health food for skin regeneration, wrinkle reduction and antioxidation comprising a compound represented by the following formula (1) as an active ingredient.
[Chemical Formula 1]
Scutellarin according to the present invention accelerates the synthesis of collagen of skin fibroblasts and inhibits collagenase activity thereby promoting regeneration of skin and eliminating free radicals to exhibit antioxidative effects, Can be used for food.
Hereinafter, the configuration of the present invention will be described in detail.
Wrinkle, and antioxidant component exhibits high activity at low concentration to exhibit skin regeneration, wrinkle improvement, antioxidant activity, excellent ability to permeate and absorb skin, It is preferable that the composition is low in volatility so that it can stay for a sufficient time to exhibit wrinkle improvement and antioxidative effect, that the active ingredient remains stable on the composition or skin, is easily formulated into medicines or cosmetics, and is safe for the skin. However, the components satisfying all of the above-mentioned characteristics among the known components are not common. For example, some skin regeneration, wrinkle improvement, and antioxidant components are excellent in skin regeneration, wrinkle improvement, and antioxidant activity even at low concentrations in vitro, but they are difficult to apply to real skin because of their ability to permeate through skin. Other active ingredients have low hydrophilicity and are difficult to formulate into medicines or cosmetics. In addition, some skin regeneration, wrinkle reduction and antioxidant components may be degraded or transformed into other compounds when exposed to heat, light, or oxygen, and the effects may already be lost before application to the skin.
As can be seen from the following examples, Scutellarin shows excellent collagen synthesis promoting effect and antioxidative effect at a low concentration. Therefore, Scutellarin is effective ingredient for medicines, cosmetics and health food for skin regeneration, wrinkle improvement and antioxidation Can be used.
Accordingly, the present invention provides a pharmaceutical composition for skin regeneration, wrinkle reduction and antioxidation, which comprises a compound represented by the following general formula (1) as an active ingredient.
[Chemical Formula 1]
The name of the compound of the above formula 1 is 7- (beta-D-Glucopyranuronosyloxy) -5,6-dihydroxy-2- (4-hydroxyphenyl) -4H-1-benzopyran- ).
The compound of formula (1) may be synthesized or a commercially available compound may be used.
The pharmaceutical composition for skin regeneration, wrinkle reduction and antioxidation of the present invention may contain a pharmaceutically acceptable salt of the compound of formula (1).
The pharmaceutically acceptable salt of the compound of Formula 1 may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid The organic acid may be selected from the group consisting of hydrochloric acid, hydrobromic acid, hydrochloric acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, hydrobromic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, , Benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid-based salts, and the inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.
The above-mentioned acid addition salts may be obtained by a) directly mixing the compound of formula 1 and an acid, or b) dissolving and mixing one of them in a solvent or a water solvent, or c) Lt; RTI ID = 0.0 > acid < / RTI > in a solvent and mixing them.
In addition to the above, additionally saltable forms include, but are not limited to, the salts of gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, Aspartate and the like.
When the compound of Chemical Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients showing the same or similar functions. For example, it may contain known skin regeneration, wrinkle reduction and antioxidant components. If additional skin regeneration, wrinkle improvement, and antioxidant ingredients are included, skin regeneration, wrinkle improvement and antioxidant effect of the composition of the present invention may be further enhanced. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the present invention, the composition is a skin regeneration component known in the art comprising retinoic acid, TGF, protein from animal placenta, betulinic acid and chlorella extract, antioxidant components known in the art, such as tocopherol, selenium , Vitamin C and phenolic compounds. The additional component may be included in an amount of 0.0001 to 10% by weight based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety, ease of formulation of the compound of Formula 1 .
In addition, the pharmaceutical composition for skin regeneration, wrinkle reduction and antioxidation of the present invention may further comprise a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carriers may contain a variety of ingredients such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, salts and polysorbates.
The pharmaceutical composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, various forms of oral and parenteral administration at the time of clinical administration. In the case of formulation, , An extender, a binder, a wetting agent, a disintegrant, a surfactant, and the like.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like.
In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used.
Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
In the present invention, the term " skin regeneration effect " refers to restoration of skin tissue against damage caused by external or internal causes of the skin. Damage due to external causes may include ultraviolet rays, external contaminants, wound, trauma, etc. The damage caused by the internal causes may be stress.
In the present invention, the term " wrinkle-reducing effect " refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already-generated wrinkles.
In the present invention, the term 'antioxidative effect' refers to the action of free radicals or reactive oxygen species (ROS), which are highly reactive according to oxidative stress caused by intracellular metabolism or ultraviolet rays, Refers to inhibition of oxidation, and includes removal of free radical or reactive oxygen species, thereby reducing damage to the cells.
The pharmaceutical composition of the present invention can provide a skin regenerating effect, a wrinkle-reducing effect and an antioxidative effect when the effective amount of the compound of Formula 1 is included. In the present invention, the term "effective amount" means an amount of a compound capable of exhibiting an effect of promoting regeneration of damaged skin, improving wrinkles, or inhibiting or alleviating oxidation of cells. An effective amount of the compound of formula (1) contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, how the compound is applied to the skin, and the time on the skin. For example, when the composition is commercialized as a pharmaceutical product, the compound of Formula 1 may be contained at a higher concentration than that of a cosmetic product that is routinely applied to skin. Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the compound of formula (1) 6 times a day.
The pharmaceutical composition of the present invention may be used alone or in combination with other methods for achieving the intended use.
The present invention can also provide a skin external preparation for skin regeneration, wrinkle reduction and antioxidation comprising the compound of formula (1) as an active ingredient.
When the compound of formula (1) is used as an external preparation for skin, it may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, , Water, ionic or nonionic emulsifiers, fillers, sequestering agents and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or external preparations for skin And any other ingredients used in the skin sciences. The components can also be introduced in amounts commonly used in the field of dermatology.
When the compound of Formula 1 is provided as an external preparation for skin, it may have a formulation such as, but not limited to, ointments, patches, gels, creams or sprays.
The present invention can also be provided as a cosmetic preparation for skin regeneration, wrinkle reduction and antioxidation comprising the compound of formula (1) as an active ingredient.
When the compound of Chemical Formula 1 is used as a cosmetic, the cosmetic product containing the compound of Chemical Formula 1 as an active ingredient may be prepared in the form of a general emulsified formulation and a solubilized formulation. For example, creams, essences, cosmetic creams, sprays, gels, packs, sunscreens, make-up bases, liquids such as lotions such as lotion, facial lotion, body lotion, A powder, a cleansing lotion, a makeup removing agent such as a cleansing oil, a cleaning agent such as a cleansing foam, a soap, a body wash and the like.
The cosmetic composition may further contain, in addition to the compound of Formula 1, a lipid, an organic solvent, a solubilizing agent, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, , Ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, barrier agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics And may contain adjuvants commonly used in the cosmetics field, such as any of the other ingredients.
In the case of a wash-off type cosmetic such as a make-up removing agent, a detergent, etc. in which the active ingredient remains on the skin in a short period of time when the compound of formula (1) is produced into a cosmetic product, . On the other hand, in the case of leave-on type cosmetics, such as lotion, cream, essence, etc., in which the active ingredient remains on the skin for a long period of time, It may be included. In one embodiment of the present invention, although not limited thereto, the composition may contain 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt%) of the compound of Formula 1 based on the total weight of the composition . When the composition of the present invention contains less than 0.0001% by weight of the compound of formula 1, sufficient skin regeneration, wrinkle improvement and antioxidative effect can not be expected. When the composition contains more than 10% by weight, This is to prevent the occurrence of a problem or a problem in skin safety.
The present invention also relates to a health food for skin regeneration, wrinkle reduction and antioxidation comprising the compound of formula (1).
Herein, the term " health food " means a food prepared by adding the compound of formula (1) to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering or suspension, But it has the advantage that there are no side effects that can occur when a drug is used for a long period of time using a food as a raw material.
Since the health food of the present invention thus obtained can be ingested on a daily basis, high skin regeneration, wrinkle improvement, and antioxidative effect can be expected, which is very useful.
When the compound of Chemical Formula 1 is used as a food additive, the compound of Chemical Formula 1 may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.
The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the health food of the present invention may contain flesh for the production of natural fruit juice, fruit juice drink and vegetable drink. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
Reference Example One: Scutellarin ( Scutellarin ) Material information
7- (beta-D-Glucopyranuronosyloxy) -5,6-dihydroxy-2- (4-hydroxyphenyl) -4H-1-benzopyran-
CAS No .: 27740-01-8
Molecular Formula: C 21 H 18 O 12
Molecular Weight: 462.37
Where to buy: Tauto Biotech Co., Ltd.
Origin and Sink: S.baicalensis Georgi
Example 1: Collagen synthesis effect
The substances of Table 1 below were added to the culture medium of human-derived fibroblasts to examine the promoting effect of collagen synthesis at the cellular level.
The synthesized collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immunoassay Kit). To evaluate the cytotoxicity of human fibroblasts before experimentation at concentrations of 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm, and 0.001 ppm of the test substance (method for MTT test by culturing fibroblasts [Reference: Mossman T. ), And the collagen aggregation performance was evaluated by selecting the concentration without cytotoxicity. In addition, the cytotoxicity assay was performed by using the Rapid Colorimetric Assay for Cellular Growth & Survival.
The final concentration of scutellarin in the experiment was 1 ppm and 10 ppm. Each sample was added to the culture medium of human fibroblasts for 1 day, and then the culture was taken with the PICP EIA kit at each concentration The degree of collagen synthesis was measured at 450 nm using a spectrophotometer. For the comparison of the effects, the degree of collagen synthesis was measured by the same method for the culture medium of fibroblasts (control group) to which nothing had been added and the sample added with vitamin C to a final concentration of 52.8 / / ml. The amount of collagen production was measured as the UV absorbance, and the increase rate of collagen production was calculated as a relative ratio of collagen production to the control. The results are summarized in Table 1 below.
As can be seen from the results of Table 1 above, Scutellarin exerted better collagen synthesis effect at a lower concentration than that of vitamin C, which is generally known to have the ability to synthesize collagen.
Example 2: Collagenase Activity inhibitory effect
The collagenase inhibitory effect of the substances shown in Table 2 was confirmed as follows.
To evaluate the cytotoxicity of human fibroblasts before experimentation at concentrations of 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm, and 0.001 ppm of the test substance (method for MTT test by culturing fibroblasts [Reference: Mossman T. ). Rapid Colorimetric Assay for Cellular Growth & Survival: Application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55-63].
Human normal skin cells, fibroblasts, were inoculated into 24-well microplates at 2.5 × 10 4 cells per well, cultured in 10% serum DMEM medium and 37 ° C. for 24 hours, and 10% serum DMEM medium was removed , Washed once with phosphate buffered saline, and then incubated for 30 minutes in serum-free DMEM medium supplemented with scutellarin and in serum-free DMEM medium without scutellarin as a control.
After 30 minutes of sample treatment, the cells were incubated for 24 hours with 50 ng / ml TNF-alpha (tumor necrosis factor-alpha), a substance known to produce MMP-1.
At this time, TNF-α-untreated group and treated group were treated with TNF-α and non-treated TNF-α among the control group without scutellarin.
The supernatant of each well was collected and the amount (ng / ml) of newly synthesized MMP-1 was measured using an MMP-1 assay kit (Amersham, USA). The inhibition rate of collagenase activity was determined by MMP -1 production inhibition rate (%) was calculated, and the results are shown in Table 2 below.
The amount of MMP-1 in the control group refers to the amount of MMP-1 in the TNF-treated group, and the amount of MMP-1 in the test group refers to the group to which the substance is added at each concentration.
[Equation 1]
As shown in Table 2, it can be confirmed that the effect of inhibiting collagenase activity of scutellarin is excellent.
Example 3: Antioxidant effect - Free radical Erasure rate
Free radical scavenging activity was measured to confirm the antioxidative activity of Scutellarin. Free radical scavenging activity was measured using DPPH. DPPH was purchased from Sigma Co. (Sigma Co., Ltd, USA) and used. First, a standard DPPH ethanol solution of 1.5 mM (0.06 mg / ml) was prepared. Then, ethanol was added to ascorbic acid, which is an antioxidant, as a standard compound and a compound of formula (1) to prepare samples at concentrations of 50 / / . Then, the sample and standard DPPH solution were added at the same ratio, stirred well, reacted at 37 ° C for 30 minutes, and absorbance was measured at 520 nm. At this time, ethanol was added instead of the sample to give a control group. The IC 50 , half maximal inhibitory concentration, was determined for the free radical scavenging ability, and the results are shown in Table 3 below. IC 50 is a common method of expressing free radical scavenging activity with the concentration of ascorbic acid and the compound of formula 1 required to remove 50% of the free radicals of the no-added control group.
As shown in Table 3, the compound of formula (I) is less active than ascorbic acid (Vitamin C), which is a typical strong antioxidant, but is stable as an antioxidant effect with excellent level as a natural substance, .
Formulation example 1: Preparation of pharmaceutical preparations
1. Manufacturing of powder
0.001 g of the compound of formula (1)
Lactose 1g
The above components were mixed and packed in airtight bags to prepare powders.
2. Preparation of tablets
0.2 mg of the compound of formula (1)
100 mg of corn starch
100 mg of milk
Stearic acid Magnesium 2 mg
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. Preparation of capsules
0.2 mg of the compound of formula (1)
100 mg of corn starch
100 mg of milk
Stearic acid Magnesium 2 mg
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
4. Manufacture of rings
0.003 g of the compound of formula (1)
Lactose 1.5 g
Glycerin 1 g
Xylitol 0.5 g
After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.
5. Manufacture of granules
2 mg of the compound of formula (1)
Soybean extract 50 mg
200 mg of glucose
600 mg of starch
After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 캜 to form granules, which were then filled in a capsule.
Formulation example 2: Manufacture of cosmetics
1. Manufacture of softening longevity (skin lotion)
As the following composition, the number of softening times containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.
0.1% by weight of the compound of formula (1)
Beta-1,3-glucan 1.0 wt%
Butylene glycol 2.0 wt%
Propylene glycol 2.0 wt%
Carboxyvinyl polymer 0.1 wt%
0.2% by weight of phage-12 nonylphenyl ether
Polysorbate 80 0.4 wt%
Ethanol 10.0 wt%
0.1% by weight triethanolamine
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
2. Manufacture of nutrition lotion (milk lotion)
As in the following composition, a nutritional lotion containing the compound of the formula (1) as an active ingredient was prepared by a conventional method.
0.1% by weight of the compound of formula (1)
Beta-1,3-glucan 1.0 wt%
4.0 wt%
Polysorbate 60 1.5 wt%
1.5% by weight of sorbitan sesquioleate
0.5% by weight liquid paraffin
Caprylic / capric triglyceride 5.0 wt%
Glycerin 3.0 wt%
3.0% by weight of butylene glycol
3.0% by weight of propylene glycol
Carboxyvinyl polymer 0.1 wt%
0.2% by weight triethanolamine
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
3. Manufacture of nutritional cream
A nutritional cream containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.
0.2% by weight of the compound of formula (1)
Beta-1,3-glucan 5.0 wt%
Wax 10.0 wt%
Polysorbate 60 1.5 wt%
≪ tb > < tb > < tb >
0.5% by weight of sorbitan sesquioleate
Liquid paraffin 10.0 wt%
Squalane 5.0 wt%
Caprylic / capric triglyceride 5.0 wt%
Glycerin 5.0 wt%
3.0% by weight of butylene glycol
3.0% by weight of propylene glycol
0.2% by weight triethanolamine
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
4. Manufacture of massage cream
A massage cream containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
0.1% by weight of the compound of formula (1)
Beta-1,3-glucan 3.0 wt%
Wax 10.0 wt%
Polysorbate 60 1.5 wt%
≪ tb > < tb > < tb >
0.8% by weight of sorbitan sesquioleate
Liquid paraffin 40.0 wt%
Squalane 5.0 wt%
Caprylic / capric triglyceride 4.0 wt%
Glycerin 5.0 wt%
3.0% by weight of butylene glycol
3.0% by weight of propylene glycol
0.2% by weight triethanolamine
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
5. Manufacture of pack
A pack containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.
0.2% by weight of the compound of formula (1)
Beta-1,3-glucan 1.0 wt%
Polyvinyl alcohol 13.0 wt%
0.2% by weight of sodium carboxymethylcellulose,
Glycerin 5.0 wt%
Allantoin 0.1 wt%
6.0% by weight of ethanol
0.3% by weight of phage-12 nonylphenyl ether
Polysorbate 60 0.3 wt%
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
Formulation example 3: Topical Produce
1. Manufacture of gel
As in the following composition, a gel containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.
0.1% by weight of the compound of formula (1)
0.1% by weight of beta-1,3-glucan
0.05% by weight of sodium ethylenediaminetetraacetate
Glycerin 5.0 wt%
Carboxyvinyl polymer 0.3 wt%
5.0% by weight of ethanol
≪ tb > < tb > < tb >
Triethanolamine 0.3 wt%
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
2. Manufacture of ointment
An ointment containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
0.5% by weight of the compound of formula (1)
Beta-1,3-glucan 10.0 wt%
Wax 10.0 wt%
Polysorbate 60 5.0 wt%
≪ tb > < tb > < tb >
0.5% by weight of sorbitan sesquioleate
Vaseline 5.0 wt%
Liquid paraffin 10.0 wt%
Squalane 5.0 wt%
SHARE BUTTER 3.0 wt%
Caprylic / capric triglyceride 5.0 wt%
Glycerin 10.0 wt%
Propylene glycol 10.2 wt%
0.2% by weight triethanolamine
Preservative 0.05 wt%
0.05% by weight of pigment
0.05% by weight fragrance
Purified water to 100%
3. Preparation of topical medicament (gel ointment)
A gel ointment agent containing the compound of the formula (1) as an active ingredient was prepared according to a conventional method.
0.5% by weight of the compound of formula (1)
Beta-1,3-glucan 10.0 wt%
1.5% by weight of polyacrylic acid (Carbopol 940)
5.0% by weight of isopropanol
Hexylene glycol 25.0 wt%
Triethanolamine 1.7 wt%
Deionized water to 100%
4. Preparation of topical medicines (patches)
As the following composition, a patch containing a compound of the formula (1) as an active ingredient was prepared by a conventional method.
0.5% by weight of the compound of formula (1)
Beta-1,3-glucan 3.0 wt%
Hexylene glycol 20.0 wt%
Diethylamine 0.7 wt%
1.0% by weight of polyacrylic acid (Carbopol 934P)
0.1% by weight of sodium sulfite
1.0% by weight of polyoxyethylene lauryl ether (E.O. = 9)
1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000)
Viscous paraffin oil 2.5 wt%
2.5% by weight of caprylic acid ester / capric acid ester (Cetiol LC)
Polyethylene glycol 400 3.0 wt%
Deionized water to 100%
Formulation example 4: Manufacturing of food
Foods containing the compound of formula (I) of the present invention were prepared as follows.
1. Manufacture of Flour Food
0.05 to 1.0 part by weight of the compound of Formula 1 was added to wheat flour, and a bread, a cake, a cookie, a cracker and a noodle were prepared using the mixture to prepare a health food.
2. Manufacture of dairy products
0.2 part by weight of the compound of Formula 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
3. Manufacturing of wire
Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer. The compound of Formula 1 was concentrated under reduced pressure in a vacuum concentrator, sprayed, and dried with a hot-air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dried powder.
The grains, seeds, and dry powder of the compound of formula (1) prepared above were blended in the following proportions relative to 100 parts by weight of the mixed powder.
(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
(1) (0.1 part by weight),
(0.5 part by weight),
Rhubarb (0.5
Weight portion
)
Formulation example 5: Manufacture of beverages
1. Manufacture of health drinks
0.1 mg of the compound of formula (1)
Citric acid 1000 mg
100 g of oligosaccharide
Plum concentrate 2 g
Taurine 1 g
Purified water All 900 mL
The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring. Then, the solution thus prepared was filtered and sterilized in a sterilized 2L-container, Lt; RTI ID = 0.0 > health < / RTI >
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
2. Manufacture of vegetable juice
1 g of the compound of formula (I) of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice for health promotion.
3. Manufacture of fruit juice
1 g of the compound of formula (1) was added to 1,000 mL of apple or grape juice to prepare fruit juice for health promotion.
Claims (12)
[Chemical Formula 1]
[Chemical Formula 1]
Wherein the external preparation is a formulation of ointment, patch, gel, cream or spray.
[Chemical Formula 1]
Cosmetics, essences, lotions, creams, packs, gels, powders, foundations or detergents.
[Chemical Formula 1]
[Chemical Formula 1]
[Chemical Formula 1]
Wherein the external preparation is a formulation of ointment, patch, gel, cream or spray.
[Chemical Formula 1]
Cosmetics, essences, lotions, creams, packs, gels, powders, foundations or detergents.
[Chemical Formula 1]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130096598A KR20150019548A (en) | 2013-08-14 | 2013-08-14 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130096598A KR20150019548A (en) | 2013-08-14 | 2013-08-14 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150019548A true KR20150019548A (en) | 2015-02-25 |
Family
ID=52578650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20130096598A KR20150019548A (en) | 2013-08-14 | 2013-08-14 | Composition for skin cell regeneration, anti-wrinkle and antioxidant |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20150019548A (en) |
-
2013
- 2013-08-14 KR KR20130096598A patent/KR20150019548A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101872918B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
KR20150019672A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, and skin whitening | |
KR20150019680A (en) | Composition for skin cell regeneration, anti-wrinkle and antioxidant | |
KR102001043B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101988909B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR102001048B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening | |
KR101909740B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising Monotropein | |
KR101988988B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening | |
KR102002427B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101989811B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101977869B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101977867B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101988907B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101989009B1 (en) | Composition for skin cell regeneration, anti-wrinkle and antioxidant | |
KR20150049404A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising isocorynoline | |
KR101998813B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising sophocarpine | |
KR101998871B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising peiminine | |
KR102001042B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101988908B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20150019634A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation | |
KR101989012B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20150019578A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR20150019548A (en) | Composition for skin cell regeneration, anti-wrinkle and antioxidant | |
KR20150052373A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening comprising linderalactone | |
KR20150019552A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |